FNA / Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?

Paragon 28, Inc. (NYSE:FNA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Matt Brinckman - SVP, Strategy and IR Alb more_horizontal

Paragon 28, Inc. (FNA) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss more_horizontal

Paragon 28, Inc. (NYSE:FNA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Matt Brinckman - Senior Vice President, Stra more_horizontal

Paragon 28, Inc. (FNA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss more_horizontal

Paragon 28, Inc. (NYSE:FNA ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Matt Brinckman - Investor Relations Albert more_horizontal

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbe more_horizontal

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthoped more_horizontal

Paragon 28, Inc. (NYSE:FNA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Brinckman - IR Albert DaCosta - C more_horizontal